CD14^(+)CD16^(-)HLA^(-)DR^(+)与PD-1单抗治疗非小细胞肺癌的疗效及预后的关系研究  

Correlation between CD14^(+)CD16^(-)HLA^(-)DR^(+)levels with the efficacy and prognosis of PD-1 monoclonal antibody in non-small cell lung cancer

作　　者：孙璐[1] 王巍[1] 李婵 姚学敏[1] 么伟楠 陈明达[1] 宋君利[1] 贾敬好[1] SUN Lu;WANG Wei;LI Chan;YAO Xuemin;YAO Weinan;CHEN Mingda;SONG Junli;JIA Jinghao(Department of Oncology,Tangshan People′s Hospital,Tangshan,Hebei 063000,China)

机构地区：[1]河北省唐山市人民医院肿瘤内科,河北唐山063000

出　　处：《国际检验医学杂志》2021年第8期949-952,共4页International Journal of Laboratory Medicine

基　　金：河北省医学科学研究课题资助项目(20191595)。

摘　　要：目的分析CD14^(+)CD16^(-)HLA^(-)DR^(+)与程序性死亡受体-1(PD-1)单抗治疗非小细胞肺癌的临床疗效和患者预后的关系,为临床应用提供依据。方法选择该院2018年6月至2019年4月收治的60例非小细胞肺癌患者作为研究对象;采用PD-1单抗进行干预治疗;采用RECIST Version1.1对患者的临床疗效进行评估;对患者进行长期随访追踪,记录患者生存率。结果CD14^(+)CD16^(-)HLA^(-)DR^(+)组患者采用PD-1单抗治疗后的疗效明显优于CD14^(+)CD16^(-)HLA^(-)DR^(-/low)组,差异有统计学意义(P<0.05);CD14^(+)CD16^(-)HLA^(-)DR^(+)组患者生存率明显优于CD14^(+)CD16^(-)HLA^(-)DR^(-/low)组患者,差异有统计学意义(P<0.05);CD14^(+)CD16^(-)HLA^(-)DR^(+)是非小细胞肺癌采用PD-1单抗治疗后的临床疗效及预后的独立影响因素(P<0.05)。结论非小细胞肺癌患者采用PD-1单抗治疗后具有较好的临床疗效,CD14^(+)CD16^(-)HLA^(-)DR^(+)患者的临床疗效以及预后生存期明显升高。Objective To analyze the correlation between the CD14^(+)CD16^(-)HLA^(-)DR^(+)with clinical efficacy of programmed death receptor-1(PD-1)monoclonal antibody drug treatment and the prognosis of patient with non-small cell lung cancer,so as to provide data support for clinical application.Methods From June 2018 to April 2019,60 patients with non-small cell lung cancer were selected as subjects;PD-1 monoclonal antibody were used for intervention treatment.The clinical efficacy of the patients was evaluated according to RECIST Version1.1.The patients were followed up for a long time and the survival rate was recorded.Results The clinical therapeutic effect of patients in CD14^(+)CD16^(-)HLA^(-)DR^(+)group was significantly better than that in CD14^(+)CD16^(-)HLA^(-)DR^(-/low)group,and the difference was statistically significant(P<0.05).Survival rate of CD14^(+)CD16^(-)HLA^(-)DR^(+)group was significant higher than that of CD14^(+)CD16^(-)HLA^(-)DR^(-/low)group(P<0.05).CD14^(+)CD16^(-)HLA^(-)DR^(+)was the influenced factor of clinical effect and prognosis quality after treatment with PD-1 monoclonal antibody in patients with non-small cell lung cancer(P<0.05).Conclusion Patients with non-small cell lung cancer have higher clinical efficacy after treatment with PD-1 monoclonal antibody.The clinical efficacy of CD14^(+)CD16^(-)HLA^(-)DR^(+)treatment and the prognosis of patients are significantly increased.

关 键 词：CD14^(+)CD16^(-)HLA^(-)DR^(+) 非小细胞肺癌 程序性死亡受体-1单抗 预后 

分 类 号：R734.2[医药卫生—肿瘤]